Abstract
Several large cohorts of patients treated with alkylating agents served as a means to review the clinical and pathologic features of 55 cases of myelopathic disorders that resulted. The incidence was 1.8% overall and consisted of five patients (9.9%) who developed bone marrow hypoplasia or aplasia, 15 (27.2%) who developed a myelodysplastic syndrome, and 35 cases of acute myeloid leukemia (62.9%). The median time to recognition of MPD was 14 months, following cessation of chemotherapy. The distribution of the treatment-related MDS cases was different than "de novo" MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic). The median survival of all patients was very brief.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Alkylating Agents / adverse effects*
-
Anemia, Aplastic / chemically induced*
-
Anemia, Aplastic / genetics
-
Child
-
Child, Preschool
-
Chlorambucil / adverse effects
-
Cyclophosphamide / adverse effects
-
Female
-
Gastrointestinal Neoplasms / complications
-
Gastrointestinal Neoplasms / drug therapy
-
Humans
-
Infant
-
Karyotyping
-
Leukemia, Myeloid, Acute / chemically induced*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / pathology
-
Male
-
Melphalan / adverse effects
-
Middle Aged
-
Myelodysplastic Syndromes / chemically induced*
-
Myelodysplastic Syndromes / genetics
-
Myelodysplastic Syndromes / pathology
-
Ovarian Neoplasms / complications
-
Ovarian Neoplasms / drug therapy
Substances
-
Alkylating Agents
-
Chlorambucil
-
Cyclophosphamide
-
Melphalan